Lapaquistat
Lapaquistat
Lapaquistat (pronounced la-pa-quis-tat) is a pharmaceutical drug that was under development for the treatment of hypercholesterolemia. It was developed by Shionogi, a Japanese pharmaceutical company, but its development was discontinued in 2006 due to safety concerns.
Etymology
The term "Lapaquistat" is derived from the Latin word "lapa", meaning "stone", and "quistat", a term used in pharmaceutical nomenclature to denote a drug's action. In this case, "quistat" refers to the drug's ability to inhibit the production of cholesterol, a substance that can form "stones" or plaques in the arteries.
Mechanism of Action
Lapaquistat works by inhibiting the enzyme squalene synthase, which is involved in the production of cholesterol in the body. By inhibiting this enzyme, Lapaquistat reduces the amount of cholesterol produced, thereby lowering the levels of cholesterol in the blood.
Related Terms
- Hypercholesterolemia: A condition characterized by high levels of cholesterol in the blood.
- Squalene synthase: An enzyme involved in the production of cholesterol.
- Shionogi: A Japanese pharmaceutical company that developed Lapaquistat.
See Also
- Statins: A class of drugs commonly used to treat hypercholesterolemia.
- Cholesterol: A waxy, fat-like substance that's found in all the cells in your body.
External links
- Medical encyclopedia article on Lapaquistat
- Wikipedia's article - Lapaquistat
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski